Keynote Financial Services LLC Purchases 7,877 Shares of Pfizer Inc. $PFE

Keynote Financial Services LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 8.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 97,224 shares of the biopharmaceutical company’s stock after buying an additional 7,877 shares during the period. Pfizer makes up approximately 1.6% of Keynote Financial Services LLC’s portfolio, making the stock its 11th biggest holding. Keynote Financial Services LLC’s holdings in Pfizer were worth $2,357,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter worth $27,000. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer during the second quarter valued at about $29,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the first quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.18.

Pfizer Trading Down 0.1%

Shares of PFE stock opened at $24.40 on Tuesday. The stock has a market capitalization of $138.73 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.54. The company’s fifty day simple moving average is $24.74 and its two-hundred day simple moving average is $24.39. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.